Drugs / HY004
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06005649 | Sep 2025 → Jun 2026 | non-Hodgkin lymphoma | Juventas Cell Therapy Ltd. | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT06009107 | Jun 2025 → Dec 2026 | B-cell acute lymphoblastic leukemia | Juventas Cell Therapy Ltd. | Withdrawn | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HY004 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06005649 ↗ |
| Modality | Cell therapy | “Autologous 2nd generation bispecific CAR-T cells” NCT06005649 ↗ |
| Route | Intravenous | “single infusion intravenously” NCT06005649 ↗ |
| Target | CD19 | “Autologous 2nd generation CD19/CD22-directed CAR-T cells” NCT06009107 ↗ |
| Target | CD22 | “Autologous 2nd generation CD19/CD22-directed CAR-T cells” NCT06009107 ↗ |